Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AC Immune (ACIU) Cash from Financing Activities: 2015-2025

Historic Cash from Financing Activities for AC Immune (ACIU) over the last 10 years, with Sep 2025 value amounting to -$948,806.

  • AC Immune's Cash from Financing Activities fell 375.17% to -$948,806 in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.8 million, marking a year-over-year decrease of 103.89%. This contributed to the annual value of -$1.3 million for FY2024, which is 102.62% down from last year.
  • Latest data reveals that AC Immune reported Cash from Financing Activities of -$948,806 as of Q3 2025, which was down 218.02% from -$298,349 recorded in Q2 2025.
  • AC Immune's Cash from Financing Activities' 5-year high stood at $46.3 million during Q4 2023, with a 5-year trough of -$991,853 in Q1 2022.
  • Moreover, its 3-year median value for Cash from Financing Activities was -$199,678 (2024), whereas its average is $4.2 million.
  • As far as peak fluctuations go, AC Immune's Cash from Financing Activities crashed by 582.68% in 2022, and later skyrocketed by 29,609.20% in 2023.
  • AC Immune's Cash from Financing Activities (Quarterly) stood at $31.2 million in 2021, then plummeted by 100.50% to -$156,741 in 2022, then soared by 29,609.20% to $46.3 million in 2023, then crashed by 100.49% to -$224,880 in 2024, then plummeted by 375.17% to -$948,806 in 2025.
  • Its Cash from Financing Activities stands at -$948,806 for Q3 2025, versus -$298,349 for Q2 2025 and -$286,961 for Q1 2025.